NJ
NJ Addiction Centers
Glossary_concepts

Addiction Treatment Glossary: Key Terms and Concepts Explained

By NJ Addiction Centers Editorial Team | Last reviewed: | 15 min read Clinically Reviewed

Addiction Treatment Glossary: Key Terms and Concepts Explained

Addiction treatment involves clinical terminology that can be difficult to parse, especially during a crisis. Terms like “ASAM criteria,” “buprenorphine,” and “partial hospitalization” appear on intake paperwork, insurance authorizations, and clinical assessments — often without explanation. This glossary translates the most important addiction treatment terms into plain language, organized by category, so New Jersey residents and their families can navigate the treatment system with clarity.

Understanding these terms is not academic. Knowing the difference between medical detox and social detox, or between Suboxone and Vivitrol, can directly affect treatment decisions, insurance approvals, and long-term outcomes.

Key Takeaways

  • Addiction treatment uses specialized clinical, pharmacological, and legal terminology that varies by state
  • New Jersey has specific licensing structures, involuntary commitment statutes, and Narcan distribution programs that differ from other states
  • The ASAM criteria framework determines placement into levels of care from outpatient through medically managed inpatient
  • Medication-assisted treatment (MAT) includes several distinct medications with different mechanisms, and terminology has shifted toward “medications for opioid use disorder” (MOUD)
  • Insurance terminology — prior authorization, medical necessity, parity — directly affects access to treatment
  • This glossary covers overdose reversal, MAT medications, clinical frameworks, facility types, diagnostic terms, and legal concepts relevant to NJ

Overdose Reversal: Narcan and Naloxone

Naloxone is the generic name for the opioid antagonist medication that reverses opioid overdoses. Narcan is the most widely recognized brand name. Understanding these terms is critical in New Jersey, which has been among the states hardest hit by the opioid crisis.

Naloxone: A medication that rapidly reverses opioid overdose by binding to opioid receptors and displacing opioids like fentanyl, heroin, and prescription painkillers. Naloxone has no effect on non-opioid substances such as cocaine, benzodiazepines, or alcohol.

Narcan (naloxone nasal spray): The brand-name nasal spray formulation of naloxone approved by the FDA. As of 2023, Narcan nasal spray (4 mg) became available over the counter without a prescription nationwide, following an FDA decision to approve its over-the-counter status.

Naloxone hydrochloride injection: The injectable form of naloxone, administered intramuscularly or intravenously. This is the formulation most commonly used by emergency medical services and hospital emergency departments.

Standing order: A legal mechanism that allows pharmacists to dispense naloxone without an individual prescription. New Jersey has had a statewide standing order for naloxone since 2017, meaning any NJ resident can obtain naloxone from a participating pharmacy without visiting a physician first.

Good Samaritan Law: New Jersey’s Overdose Prevention Act (N.J.S.A. 2C:35-30 and 2C:35-31) provides legal immunity to individuals who call 911 to report an overdose and to the person experiencing the overdose. The law covers both the caller and the victim from drug possession charges.

For a deeper examination of naloxone formulations, including nasal spray versus injectable and proper administration techniques, see our guide to Narcan and naloxone. The differences between naloxone, naltrexone, and nalmefene are also frequently confused and worth understanding. For detailed information on Narcan forms and administration, including dosing for fentanyl-related overdoses, see the dedicated spoke page.

MAT Medications: Vivitrol, Suboxone, and Sublocade

Medication-assisted treatment (MAT) combines FDA-approved medications with counseling and behavioral therapies. The term “MAT” is gradually being replaced in clinical literature by “medications for opioid use disorder” (MOUD) or “medications for addiction treatment,” reflecting the understanding that medication is not merely an “assist” but a primary, evidence-based treatment.

Medication-Assisted Treatment (MAT): The use of FDA-approved medications, in combination with counseling and behavioral therapies, to treat substance use disorders. According to SAMHSA, MAT has been shown to reduce opioid use, opioid-related overdose deaths, criminal activity, and infectious disease transmission.

Buprenorphine: A partial opioid agonist that activates opioid receptors at a lower intensity than full agonists like heroin or fentanyl. Buprenorphine reduces cravings and withdrawal symptoms without producing the same level of euphoria. It is the active ingredient in Suboxone, Subutex, and Sublocade.

Suboxone (buprenorphine/naloxone): A sublingual film or tablet combining buprenorphine with naloxone. The naloxone component is included as an abuse deterrent — it has minimal effect when the medication is taken as directed (sublingually) but triggers withdrawal if the medication is injected. Suboxone is the most widely prescribed MOUD in the United States.

Sublocade (extended-release buprenorphine injection): A once-monthly subcutaneous injection of buprenorphine. Sublocade eliminates the need for daily dosing and reduces diversion risk. It is typically initiated after a patient has been stabilized on transmucosal buprenorphine for at least seven days.

Naltrexone: An opioid antagonist that blocks opioid receptors entirely, preventing both the effects and the euphoria of opioid use. Unlike buprenorphine and methadone, naltrexone has no opioid agonist properties and carries no risk of physical dependence.

Vivitrol (extended-release naltrexone injection): A once-monthly intramuscular injection of naltrexone. Vivitrol is FDA-approved for both opioid use disorder and alcohol use disorder. A key clinical consideration is that patients must be fully detoxed from opioids (typically 7 to 14 days) before receiving Vivitrol, as administering it to a patient with opioids in their system can trigger precipitated withdrawal.

Methadone: A long-acting full opioid agonist dispensed through federally certified opioid treatment programs (OTPs). Methadone reduces cravings and withdrawal symptoms and has the longest evidence base of any MOUD, with research dating to the 1960s. In New Jersey, methadone can only be dispensed at licensed OTPs — it cannot be prescribed for opioid use disorder by a standard physician’s office, unlike buprenorphine.

DATA 2000 waiver (X-waiver) — now eliminated: Previously, physicians needed a special DEA waiver to prescribe buprenorphine for opioid use disorder. The Consolidated Appropriations Act of 2023 eliminated this requirement, meaning any DEA-licensed practitioner can now prescribe buprenorphine without additional certification. This significantly expanded access in New Jersey and nationwide.

For a comprehensive comparison of Vivitrol, Suboxone, and Sublocade — including mechanism differences, insurance coverage patterns, and which medication fits which clinical scenario — see our guide to Vivitrol vs. Suboxone vs. Sublocade. For specific information about Vivitrol and the Vivitrol program structure, dedicated spoke pages cover eligibility, administration, and coverage in detail.

Clinical Frameworks: ASAM Criteria and Levels of Care

The ASAM criteria, published by the American Society of Addiction Medicine, are the most widely used set of guidelines for placing patients into appropriate levels of addiction treatment. Insurance companies, treatment providers, and state licensing bodies in New Jersey all reference ASAM levels when making placement, authorization, and coverage decisions.

ASAM Criteria: A multidimensional assessment framework that evaluates patients across six dimensions: (1) acute intoxication and withdrawal potential, (2) biomedical conditions, (3) emotional/behavioral/cognitive conditions, (4) readiness to change, (5) relapse/continued use potential, and (6) recovery environment. The assessment determines the appropriate level of care.

Level 0.5 — Early Intervention: Brief interventions and motivational interviewing for individuals at risk but not yet meeting diagnostic criteria for a substance use disorder.

Level 1 — Outpatient Treatment: Fewer than 9 hours of structured programming per week. Appropriate for individuals with stable living situations and mild to moderate substance use disorders.

Level 2.1 — Intensive Outpatient Program (IOP): A minimum of 9 hours per week of structured programming, typically three to five days per week. IOP allows patients to live at home while receiving concentrated treatment.

Level 2.5 — Partial Hospitalization Program (PHP): A minimum of 20 hours per week of structured clinical programming. PHP provides a higher intensity than IOP while still allowing patients to return home or to a sober living environment each evening.

Level 3.1 — Clinically Managed Low-Intensity Residential: 24-hour residential care with at least 5 hours of clinical programming per week. Often used for individuals who need a structured environment but not intensive clinical services.

Level 3.5 — Clinically Managed High-Intensity Residential: 24-hour care with structured programming and trained counselors. This is the level most people associate with “inpatient rehab.”

Level 3.7 — Medically Monitored Intensive Inpatient: 24-hour nursing care with physician availability. Appropriate for patients with significant medical and psychiatric co-occurring conditions.

Level 4 — Medically Managed Intensive Inpatient: Hospital-based care with 24-hour medical management. Reserved for severe withdrawal, acute psychiatric crises, or complex medical conditions requiring constant monitoring.

New Jersey’s Division of Mental Health and Addiction Services (DMHAS) licenses treatment facilities according to these ASAM levels. Understanding which level a facility operates at is essential for insurance pre-authorization and clinical appropriateness. For a detailed walkthrough of the ASAM criteria assessment process and how it applies to NJ treatment placement, see the dedicated spoke page.

Facility Types: Sober Houses, Recovery Residences, and More

The terminology around post-treatment housing is frequently confused. “Sober house,” “halfway house,” “recovery residence,” and “sober living” are often used interchangeably, but they refer to distinct housing models with different levels of structure, oversight, and legal protections.

Sober Living / Sober House: A residential environment that requires abstinence from drugs and alcohol as a condition of residency. Sober houses are not clinical treatment facilities — they do not provide therapy, medical care, or structured programming. They provide a substance-free living environment, often with house rules, drug testing, and peer accountability.

Recovery Residence: A broader term encompassing all levels of sober housing, from minimally structured peer-run homes to highly structured clinical residences. The National Alliance for Recovery Residences (NARR) defines four levels of recovery residences based on the intensity of support provided.

Halfway House: Traditionally, a transitional living facility for individuals leaving incarceration or inpatient treatment. In some states, halfway houses are state-funded and provide case management, employment assistance, and supervision. The term is sometimes used interchangeably with sober living, though they often serve different populations.

Oxford House: A self-governed, democratically run sober living model. Oxford Houses have no paid staff, no time limits on residency, and are financially self-supporting through resident contributions. There are Oxford House locations throughout New Jersey.

Therapeutic Community (TC): A long-term (6 to 24 months) residential program that uses the community itself — peers, staff, and shared structure — as the primary therapeutic tool. TCs emphasize personal accountability, social learning, and progressive responsibility.

New Jersey regulates recovery residences through a voluntary certification process. The NJ Alliance for Recovery Residences works with the state to establish standards. However, not all sober living homes in NJ are certified, and quality varies significantly. For more on sober house definitions and standards in New Jersey, including what to look for and what to avoid, see the dedicated spoke page.

Clinical Terms: SUD Severity, Diagnosis, and Assessment

Clinical language around addiction has shifted substantially in recent decades. The DSM-5, published by the American Psychiatric Association, replaced the older distinction between “substance abuse” and “substance dependence” with a single diagnosis — substance use disorder — measured on a severity spectrum.

Substance Use Disorder (SUD): The clinical diagnosis for addiction as defined in the DSM-5. SUD is diagnosed based on the presence of 11 possible criteria, including impaired control, social impairment, risky use, and pharmacological indicators (tolerance and withdrawal). Severity is classified as mild (2-3 criteria), moderate (4-5 criteria), or severe (6 or more criteria).

DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition): The standard classification system used by mental health professionals in the United States. The DSM-5 was published in 2013 and replaced the DSM-IV, which had treated substance abuse and substance dependence as separate diagnoses.

Tolerance: A pharmacological phenomenon in which the body requires progressively larger doses of a substance to achieve the same effect. Tolerance is one of the 11 DSM-5 criteria for substance use disorder but is not sufficient for a diagnosis on its own.

Physical Dependence: A state in which the body has adapted to the presence of a substance and experiences withdrawal symptoms upon cessation. Physical dependence can occur with many medications (including non-addictive ones like antidepressants and beta-blockers) and is distinct from addiction.

Withdrawal: The cluster of physical and psychological symptoms that occur when a person who is physically dependent on a substance stops or significantly reduces use. Withdrawal severity and risk vary dramatically by substance — alcohol and benzodiazepine withdrawal can be life-threatening, while opioid and stimulant withdrawal, though intensely uncomfortable, are rarely fatal.

Co-Occurring Disorders / Dual Diagnosis: The presence of both a substance use disorder and at least one other mental health disorder (such as depression, PTSD, anxiety, or bipolar disorder). According to SAMHSA’s 2023 National Survey on Drug Use and Health, approximately 21.5 million adults in the United States had a co-occurring mental health disorder and substance use disorder.

Nursing Care Plan (NCP) for Substance Abuse: A clinical document used in healthcare settings that outlines nursing diagnoses, expected outcomes, and interventions for patients with substance use disorders. NCPs include assessments for withdrawal severity, fall risk, nutritional status, and psychosocial support needs.

For additional clinical terminology, including expected findings in SUD assessments and the nursing process for substance use disorders, see our page on substance use disorder clinical terms.

New Jersey does not have a “Baker Act” — that is Florida’s involuntary commitment statute. New Jersey’s involuntary commitment process is governed by a different legal framework, and understanding the distinction matters for NJ families navigating a psychiatric or substance use crisis.

Involuntary Commitment (NJ): New Jersey’s screening law (N.J.S.A. 30:4-27.1 et seq.) allows for the involuntary commitment of individuals who present a danger to themselves or others due to mental illness. A person can be taken to a screening center for evaluation, and if they meet the clinical and legal criteria, they can be committed to inpatient psychiatric care for an initial period, with subsequent court review.

Screening Center: New Jersey operates designated psychiatric screening centers throughout the state, typically housed within hospital emergency departments. These centers evaluate individuals for involuntary commitment and serve as the entry point for the crisis mental health system.

Clinical Certificate: A document completed by a physician or psychiatrist certifying that an individual meets the criteria for involuntary commitment. In New Jersey, two clinical certificates are required for commitment beyond the initial screening period.

Marchman Act (Florida): Florida’s involuntary substance abuse treatment statute, which allows family members to petition a court for court-ordered assessment and treatment. New Jersey does not have an equivalent statute specifically for substance use disorders — NJ’s involuntary commitment statute applies primarily to mental illness, though co-occurring substance use may be a factor in the evaluation.

Psychiatric Hold / Emergency Admission: The initial period during which a person can be held for evaluation at a screening center without a court order. In New Jersey, this period allows for assessment and determination of whether involuntary commitment proceedings should begin.

5150 (California): California’s code section for involuntary psychiatric holds, often referenced in popular culture. This does not apply in New Jersey. Each state has its own involuntary commitment framework with different procedures, timelines, and legal standards.

For a comprehensive breakdown of New Jersey’s psychiatric hold process, including who can initiate a hold, what happens at a screening center, and patient rights during the process, see the dedicated spoke page.

Insurance and Access Terms

Insurance terminology creates a significant barrier to accessing treatment. Understanding these terms helps patients and families navigate prior authorizations, appeals, and coverage disputes.

Prior Authorization (Pre-Certification): A requirement by health insurance plans that certain treatments, medications, or levels of care must be approved by the insurer before the patient receives them. For addiction treatment in New Jersey, inpatient rehab and residential programs typically require prior authorization.

Medical Necessity: The clinical standard that insurers use to determine whether a treatment is covered. For addiction treatment, medical necessity is typically established through ASAM criteria assessment. If a patient meets ASAM criteria for a particular level of care, that level is considered medically necessary.

Mental Health Parity and Addiction Equity Act (MHPAEA): A federal law, originally passed in 2008, requiring health insurers to cover mental health and substance use disorder treatment at the same level as medical and surgical treatment. Parity applies to financial requirements (copays, deductibles) and treatment limitations (visit limits, prior authorization).

Utilization Review: The process by which an insurer evaluates ongoing treatment to determine whether continued care at the current level is medically necessary. Utilization reviews often occur at regular intervals during inpatient or residential treatment and can result in step-down to a lower level of care.

Network / Out-of-Network: In-network providers have negotiated rates with an insurer, resulting in lower out-of-pocket costs for the patient. Out-of-network treatment may be covered at a lower rate or not at all, depending on the plan. New Jersey’s network adequacy laws require insurers to maintain sufficient addiction treatment providers in their networks.

Medicaid (NJ FamilyCare): New Jersey’s Medicaid program, known as NJ FamilyCare, covers addiction treatment services including detox, inpatient, outpatient, IOP, PHP, and MAT. Eligibility depends on income, household size, and immigration status.

Therapy and Treatment Modality Terms

Cognitive Behavioral Therapy (CBT): A structured, goal-oriented psychotherapy that helps patients identify and change maladaptive thought patterns and behaviors associated with substance use. CBT is one of the most widely studied and evidence-supported therapies for addiction treatment.

Dialectical Behavior Therapy (DBT): A modified form of CBT originally developed for borderline personality disorder, now widely used in addiction treatment. DBT emphasizes four skill areas: mindfulness, distress tolerance, emotional regulation, and interpersonal effectiveness.

Eye Movement Desensitization and Reprocessing (EMDR): A psychotherapy approach that uses bilateral stimulation (typically guided eye movements) to help patients process traumatic memories. EMDR is increasingly used in addiction treatment settings, particularly for patients with co-occurring PTSD.

Contingency Management (CM): A behavioral intervention that provides tangible incentives (vouchers, prizes, or privileges) for meeting treatment goals such as negative drug screens. Research published in the Journal of Substance Abuse Treatment has shown contingency management to be particularly effective for stimulant use disorders, where no FDA-approved medications exist.

Motivational Interviewing (MI): A patient-centered counseling approach that helps individuals resolve ambivalence about behavior change. MI does not confront or persuade — it draws out the patient’s own motivation for change.

Trauma-Informed Care: An organizational framework recognizing that many individuals in addiction treatment have histories of trauma. Trauma-informed programs screen for trauma, avoid re-traumatization, and integrate trauma treatment into the overall plan of care.

Topics in This Guide

For a broader understanding of how these terms apply within the treatment continuum, see our guides to types of addiction treatment and opioid addiction.

Looking for treatment options in your area? We can help point you in the right direction. (800) 555-0199 — or request a callback.